Perceptive Streamlines Workflow and Enables Greater Efficiency With New Web-Based Study Design Tool in DataLabs EDC Solution

Perceptive Streamlines Workflow and Enables Greater Efficiency With New Web-Based Study Design Tool in DataLabs EDC Solution

Perceptive Informatics, a leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), today released a new web-based version of the DataLabs DesignerTM module, which is part of Perceptive's DataLabs® Electronic Data Capture (EDC) solution. The web-based study design tool, which can be hosted by Perceptive, provides clinical study teams worldwide with online access to collaboratively design trials. This core capability assists in streamlining workflow and improving the efficiency of the study design process.

The study design tool empowers sponsors to have enhanced oversight of the study design process and to track progress. Web-based access facilitates the use of a centralized, controlled library of study design components that can be validated, tested and available for reuse on all new studies. The library includes forms with edit checks to assist teams in designing studies faster, thereby helping to decrease study start-up and development timelines. The standardized forms can be adapted for multiple trials to further enhance efficiency.

"Optimizing the trial process is a key priority for the biopharmaceutical industry. The release of this new web-based version of our study design tool reinforces Perceptive's commitment to provide advanced functionality in our EDC solution to simplify user workflow," said David Stein, Senior Director, Product Management, Perceptive Informatics. "To accommodate the needs of companies of all sizes, the DataLabs Designer tool was developed with the flexibility to be implemented in the customer's environment or hosted by Perceptive."

The DataLabs system, suitable for all types and sizes of clinical trials, has a hybrid capability that enables studies to include sites using paper Case Report Forms (CRFs) and support existing paper processes. With a single electronic clinical data management platform to unify the functionality of paper data entry with the flexibility of EDC, the DataLabs system provides sponsors with the flexibility to choose their preferred method of data collection.

The DataLabs EDC solution is part of Perceptive's eClinical Suite, which provides interoperability among systems, including the IMPACT® Clinical Trial Management System (CTMS) andClinPhone® RTSM technologies. The eClinical Suite is a dramatic shift toward maximally leveraging technology to accelerate development. The suite supports real-time data interchange, simplifies workflow, and enables diverse applications to work synergistically while facilitating effective trial management.

                                                              # # #

About Perceptive Informatics
Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. The Perceptive Informatics industry-leading eClinical product portfolio is built on advanced technology that benefits from extensive medical and clinical expertise as well as a deep understanding of the regulatory environment. The portfolio includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO). For more information about the integrated solutions in Perceptive's eClinical Suite visit:

About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 54 countries around the world, and has approximately 9,500 employees. For more information about PAREXEL International visit

This release contains "forward-looking" statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand.  For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements.  Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "will," "would," "could," "targets," and similar expressions are also intended to identify forward-looking statements.  The forward-looking statements in this release involve a number of risks and uncertainties.  The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release.  Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, including the anticipated restructuring charge of approximately $24 million over the second, third, and fourth quarters of Fiscal Year 2010; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks.  Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2010 as filed with the SEC on May 7, 2010 which "Risk Factors" discussion is incorporated by reference in this press release.  The Company specifically disclaims any obligation to update these forward-looking statements in the future.  These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.